# Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

> **NCT05359263** · PHASE2 · RECRUITING · sponsor: **Tor Biering-Sørensen** · enrollment: 222 (estimated)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05359263
- **Lead sponsor:** Tor Biering-Sørensen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-08
- **Primary completion:** 2025-02-18
- **Final completion:** 2025-02-18
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359263, "Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05359263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*